GemPharmatech branches out with preclinical research sites in U.S.

By The Science Advisory Board staff writers

February 22, 2021 -- China's GemPharmatech, a provider of laboratory animals, has launched new research sites in the U.S. that will house 6,000 research models.

The Nanjing, China-based company said that it has a large collection of about 15,000 models, including conditional knockout, knockout mice, and immune-deficient mice, generated using gene editing technologies. The new facilities are based in Massachusetts and California.

The company hopes to provide tools and services faster and closer to its research and development customers, including large pharmaceutical and biotechnology companies, contract research organizations (CROs), universities, and research institutions in the U.S.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?